# VALN catalysts: Valneva SE PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/valn/catalysts

> Valneva SE (VALN) has no upcoming catalysts in this calendar. The latest recorded is the VLA1601 topline data readout, 1H 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for VALN?

Valneva SE (VALN) has no upcoming catalysts in this calendar. The latest recorded is the VLA1601 topline data readout, 1H 2026. Press release filed with the SEC (EX-99): "•First Phase 3 data readout for Lyme disease vaccine candidate (VLA15) anticipated in the first half of 2026, with regulatory submissions expected to follow as planned by Pfizer, subject to positive results oIf approved, VLA15 will be the fourth vaccine successfully developed by Valneva and subsequent commercialization by Pfizer would enable Valneva to further expand and accelerate its pipeline of innovative vaccines in line with the Company's strategic vision" [Calendar and source filings](https://sec-api.dev/companies/valn/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001628280-26-019159, https://www.sec.gov/Archives/edgar/data/1836564/000162828026019159/a2026_03x18xfyx2025xresult.htm (retrieved 2026-11-12). Last confirmed 2026-03-18. Cite: https://sec-api.dev/companies/valn/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Valneva SE |
| Ticker | VALN (Nasdaq) |
| SEC CIK | 1836564 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/valn |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2022 | [Valneva SE topline data readout](https://sec-api.dev/companies/valn/catalysts) | VALN |  | completed, positive | "We announced completion of recruitment for VLA15-221 in July 2021 and reported positive topline and booster data in February 2022 and September 2023, respectively." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1836564/000162828025014522/valn-20241231.htm)) |
| May 2022 | [Chikungunya topline data readout](https://sec-api.dev/pdufa/chikungunya) | VALN |  | completed, positive | "We announced completion of recruitment for this trial in June 2021 and positive topline and final data from this trial in December 2021 and May 2022, respectively." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1836564/000162828025014522/valn-20241231.htm)) |
| Sep 2023 | [Valneva SE topline data readout](https://sec-api.dev/companies/valn/catalysts) | VALN |  | completed, positive | "We announced completion of recruitment for VLA15-221 in July 2021 and reported positive topline and booster data in February 2022 and September 2023, respectively." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/valn-20251231.htm)) |
| Jan 2024 | [Chikungunya trial start](https://sec-api.dev/pdufa/chikungunya) | VALN |  | completed | "Additionally, we initiated a Phase 2 pediatric trial in children 1 to 11 years of age, VLA1553-221, in January 2024 to support a Phase 3 pivotal pediatric study and potentially extend the label in this age group following initial regulatory approvals in adults and possibly in adolescents." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1836564/000162828025014522/valn-20241231.htm)) |
| Jan 2024 | [IXCHIQ (ixchiq) trial start](https://sec-api.dev/pdufa/ixchiq) | VALN |  | completed | "In January 2024, we initiated a Phase 2 pediatric trial in children one to eleven years of age to evaluate the safety and immunogenicity of two different dose levels of IXCHIQ." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/valn-20251231.htm)) |
| Mar 2024 | [VLA160124 trial start](https://sec-api.dev/pdufa/vla160124) | VALN |  | completed | "In March 2024, Valneva initiated a Phase 1 clinical trial to investigate the safety and immunogenicity of VLA160124." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000162828025022959/valnevaq1pressrelease7-5x2.htm)) |
| Mar 2024 | [VLA160125 trial start](https://sec-api.dev/pdufa/vla160125) | VALN |  | completed | "In March 2024, Valneva initiated a Phase 1 clinical trial to investigate the safety and immunogenicity of VLA160125." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000162828025039789/h1_resultsxprxfinalxdraft.htm)) |
| Mar 2024 | [VLA160126 trial start](https://sec-api.dev/pdufa/vla160126) | VALN |  | completed | "In March 2024, Valneva initiated a Phase 1 clinical trial to investigate the safety and immunogenicity of VLA160126." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000162828025013977/valnevapr3-20x2025.htm)) |
| Mar 2024 | [VLA1601 trial start](https://sec-api.dev/pdufa/vla1601) | VALN |  | completed | "In March 2024, we initiated a Phase 1 clinical trial to investigate the safety and immunogenicity of our optimized vaccine candidate." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1836564/000162828025014522/valn-20241231.htm)) |
| November 26, 2024 | [Valneva SE FDA approval](https://sec-api.dev/companies/valn/catalysts) | VALN |  | completed, approved | "4 Valneva Announces U.S. FDA Approval of World's" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000117184324006606/exh_991.htm)) |
| December 3, 2024 | [Chikungunya FDA approval](https://sec-api.dev/pdufa/chikungunya) | VALN |  | completed, approved | "4 Valneva Announces U.S. FDA Approval of World's" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000117184324006682/exh_991.htm)) |
| 1H 2025 | [VLA1601 trial start](https://sec-api.dev/pdufa/vla1601) | VALN |  | scheduled | "In addition to the CHIM study, LimmaTech is planning to initiate a Phase 2 pediatric study in LMICs in the first half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000162828025013977/valnevapr3-20x2025.htm)) |
| January 21, 2025 | [IXCHIQ (ixchiq) FDA approval](https://sec-api.dev/pdufa/ixchiq) | VALN |  | completed, approved | "11 Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ® - Valneva" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000162828025002290/valnevapr22-1x25.htm)) |
| February 5, 2025 | [IXCHIQ (ixchiq) FDA approval](https://sec-api.dev/pdufa/ixchiq) | VALN |  | completed, approved | "2 Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ® - Valneva" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000162828025003919/valnevapr5-2x2025.htm)) |
| February 28, 2025 | [IXCHIQ (ixchiq) FDA approval](https://sec-api.dev/pdufa/ixchiq) | VALN |  | completed, approved | "6 Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ®" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000162828025008984/valnevapr28-2x25.htm)) |
| March 20, 2025 | [IXCHIQ (ixchiq) FDA approval](https://sec-api.dev/pdufa/ixchiq) | VALN |  | completed, approved | "2 Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ®" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000162828025014459/valnevapr24-3x25.htm)) |
| March 31, 2025 | [IXCHIQ (ixchiq) FDA approval](https://sec-api.dev/pdufa/ixchiq) | VALN |  | completed, approved | "[2] Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ® - Valneva" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000162828025015897/valnevapr4-1x2025.htm)) |
| April 14, 2025 | [IXCHIQ (ixchiq) FDA approval](https://sec-api.dev/pdufa/ixchiq) | VALN |  | completed, approved | "5 Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ® - Valneva" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000162828025017969/valnevapr2025_04x16xwvc2025.htm)) |
| late 2025 | [VLA1601 topline data readout](https://sec-api.dev/pdufa/vla1601) | VALN |  | scheduled | "•First data readout for Lyme disease Phase 3 VALOR study expected at the end of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000162828025013977/valnevapr3-20x2025.htm)) |
| 1H 2026 | [VLA1601 topline data readout](https://sec-api.dev/pdufa/vla1601) | VALN |  | scheduled | "•First Phase 3 data readout for Lyme disease vaccine candidate (VLA15) anticipated in the first half of 2026, with regulatory submissions expected to follow as planned by Pfizer, subject to positive results oIf approved, VLA15 will be the fourth vaccine successfully developed by Valneva and subsequent commercialization by Pfizer would enable Valneva to further expand and accelerate its pipeline of innovative vaccines in line with the Company's strategic vision" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000162828026019159/a2026_03x18xfyx2025xresult.htm)) |

## Drugs

- [Chikungunya](https://sec-api.dev/pdufa/chikungunya): 
- [IXCHIQ (ixchiq)](https://sec-api.dev/pdufa/ixchiq): 
- [VLA1601](https://sec-api.dev/pdufa/vla1601): 
- [VLA160124](https://sec-api.dev/pdufa/vla160124): 
- [VLA160125](https://sec-api.dev/pdufa/vla160125): 
- [VLA160126](https://sec-api.dev/pdufa/vla160126): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/valn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VALN catalysts: Valneva SE PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/valn/catalysts

```bibtex
@misc{secapidev_companies_valn_catalysts_20261116,
  title        = {VALN catalysts: Valneva SE PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/valn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_valn_catalysts_20261116","title":"VALN catalysts: Valneva SE PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/valn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
